At ESMO 2014, Prof Jonathan Ledermann (University College London, UK) provides an update on the management of ovarian cancer, including maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.
ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management
16th March 2015
Oncology
